Development of freeze-dry kits containing imatinib and different chelating agents: characterization, stability and cytotoxicity studies

Development of freeze-dry kits containing imatinib and different chelating agents: characterization, stability and cytotoxicity studies

The current study aims to develop new freeze-dry kits containing Imatinib and different chelating agents for breast cancer treatment and diagnosis as theranostics. Four formulations (Kit-1, Kit-2, Kit-3, and Kit-4) were prepared, and the characterization of formulations was assessed utilizing particle size, polydispersity index, zeta potential, fourier transform infra-red analysis, ultraviolet spectrum analysis, differential calorimetry, and thermogravimetric analysis. They were also evaluated for stability at different storage conditions and cytotoxicity effect on fibroblast NIH-3T3 cells. The particle size, polydispersity index, and zeta potential of developed formulations were found to be between 6953.6 ±131.6 and 5888.3 ± 131.6 nm, 0.481 ± 0.24 and 0.319 ± 0.18, -594.5±59.6 and -477.3 ± 25.32 mV, respectively. Fourier transform infra-red analysis, ultraviolet spectrum, differential calorimetry, and thermogravimetric analysis have proven that IMT and chelating agents formed complexes in kit formulations. Also, they exhibited stable facility and above 90% of cell viability on fibroblast NIH-3T3 cells. By the result of our study, kit formulations can be a favorable drug delivery system in the treatment and diagnosis of breast cancer with a non-toxic effect on healthy cells.

___

  • [1] Cohen Martin H, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, Khin Maung U, Staten AM, Pazdur R. Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia. Clin Cancer Res. 2002; 8(5): 935–942.
  • [2] Waller CF. Imatinib Mesylate. Recent Results in Cancer Res. 2018; 212: 1-27. [CrossRef]
  • [3] Sumer B, Gao J. Theranostic nanomedicine for cancer. Nanomedicine (Lond). 2008; 3(2): 137-140. [CrossRef]
  • [4] Haque MA, Vasudha BD, Surekha B, Gouthami C, Hari Priya R, Yakamma B. Development of uv-spectrophotometric method for the determination of imatinib mesylate in bulk and formulation. Int J Pharm Res Health Sci. 2016; 4(2): 1130–1135.
  • [5] Danaei MM, Dehghankhold SA, Hasanzadeh Davarani F, Javanmard R, Dokhani A, Khorasani S, M. R. Mozafari SMR. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018; 10(2): 57. [CrossRef]
  • [6] Bhojya Naik H, Siddaramaiah S, Ramappa PG. Thermogravimetric analysis of Cobalt(II)-Dothiepin complexes. J Therm Anal Calorim. 1999; 55(3): 841–49. [CrossRef]
  • [7] Guimarães KL, Inês Ré M. Lipid nanoparticles as carriers for cosmetic ingredients: The first (SLN) and the second generation (NLC). In: Beck R, Guterres S, Pohlmann A. (Eds). Nanocosmetics and Nanomedicines New Approaches For Skin Care. Springer, Verlag Berlin Heidelberg, 2011 pp. 101–122.
  • [8] Imatinib, DrugBank Online. https://go.drugbank.com/drugs/DB00619 (accessed on 1 March 2021).
  • [9] Gundogdu E,Karasulu HY, Koksal C, Karasulu E. The novel oral imatinib microemulsions: Physical properties, cytotoxicity activities and improved Caco-2 cell permeability. J Microencapsul Micro and Nano Carriers. 2013; 30(2): 132-142.
  • [10] Othman MF, Elise V, Costa I, Tanapirakgul M, Cooper MS, Imberti C, Lewington VJ, Blower PJ, Terry SYA. In vitro cytotoxicity of auger electron-emitting [67Ga]Ga-Trastuzumab. Nucl Med Biol. 2020; 80(81): 57–64. [CrossRef]
  • [11] Mohini G, Sharma R, Amirdhanayagam J, Sarma HD, Rangarajan V, Dash A, Das T. Formulation and clinical translation of [177Lu] Lu-Trastuzumab for radioimmunotheranostics of metastatic breast cancer. RSC Med Chem. 2021;12: 263-277. [CrossRef]
  • [12] International Atomic Energy Agency. Development of kits for 99mTc radiopharmaceuticals for infection imaging, IAEA-TECDOC-1414, IAEA, Vienna. 2004.
  • [13] Smita JP, Rajendra CD, Priya PD. Development of uv-spectrophotometric method for the determination of imatinib mesylate (ITM) in Bulk and Formulation. Asian J Pharm Clin Res. 2013; 6(3): 54–57.
  • [14] Bożena K, Górniak A, Marciniak DM, Mucha I. Molecular mobility and stability studies of amorphous imatinib mesylate. Pharmaceutics. 2019; 11(7): 304. [CrossRef]
  • [15] Maude R, Wiest J, Saedtler M, Harlacher C, Gutmann M, Zottnick SH, Piechon P, Dix I, Buschbaum KM, Holzgrabe U, Meinel L, Galli B. Bioinspired co-crystals of imatinib providing enhanced kinetic solubility. Eur J Pharm Biopharm. 2018; 128: 290–299. [CrossRef]
Journal of research in pharmacy (online)-Cover
  • Yayın Aralığı: 6
  • Yayıncı: Marmara Üniversitesi
Sayıdaki Diğer Makaleler

Acute hyperglycemia causes oxidative stress which is prevented by vitamin E pretreatment in healthy rabbits

Gökçen TELLİ, İnci KAZKAYASI, Serdar UMA, Aylin BALCI

Liquid Chromatographic Determination of pKa Value of 1- (2-methylbenzonitrile)-3-benzylbenzimidazolium bromide as a Drug Candidate in Acetonitrile-Water Binary Mixtures

Ebru ÇUBUK DEMİRALAY, Zehra ÜSTÜN, İlkay KONÇE, Senem AKKOÇ

Formulation of a natural nanosystem based on β- cyclodextrin/arginine/xanthan to increase antifungal activity of Salvia officinalis essential oil from Algeria (Bejaïa, Kalaa n'Ath Abas)

Yacine NAIT BACHIR, Naima SAHRAOUI, Zahia CHEURFA, Meriem MEDJKANE, Amel HADJ ZIANE

The effect of Cotinus coggygria L. ethanol extract in the treatment of burn wounds

Fatih GÖĞER, Feriha ERCAN, Ali ŞEN, Betül OKUYAN, Büşra ERTAŞ, Göksel ŞENER, Hüseyin ÖNEL

The effects of N(1)-2,4-dihydroxybenzylidene-N-(4) hydroxybenzylidene-S-methyl-thiosemicarbazidatooxovanadium( IV) on testicular damage in streptozotocininduced diabetic rats

Bahri ÜLKÜSEVEN, Refiye YANARDAĞ, Sevim TUNALI, Tülay BAL-DEMİRCİ

Evaluation of emulgel formulations contain diclofenac sodium via quality by design approach

Neslihan ÜSTÜNDAĞ OKUR, Gizem YEĞEN, Buket AKSU, Mohammed KALAYI

A sensitive surfactant-mediated spectrofluorimetric determination of chemotherapeutic agent topotecan in human serum and its investigation of DNA binding mechanism

Engin ER

Metal nanoparticles for miRNA detection

Ayca KARASAKAL

A hybrid ligand and structure-based virtual screening of NCI compound library identifies potential SAPT1 inhibitors

Suat SARI, Nisha VALAND, Umakhanth Venkatraman GIRIJA

Antioxidant activity and nephroprotective effect of Lansium parasiticum leaves in doxorubicin-induced rats

Muhammad Fauzan LUBIS, Hafid SYAHPUTRA, Didi Nurhadi ILLIAN, Vera Estefania KABAN